The 39th and 40th Barcelona BioMed Conferences, partnerships between IRB Barcelona and the BBVA Foundation, showcased groundbreaking developments in biomedical research. The 39th conference highlighted the therapeutic potential of targeted protein degradation, while the 40th conference offered deep insights into the nature of cancer and treatment strategies. Each conference drew over 150 experts from around the world, emphasising the importance of collaborative efforts in advancing our understanding of disease and treatment.
During the 39th “Proximity-inducing pharmacology: Targeted protein degradation and beyond” conference experts gathered by Dr. Cristina Mayor-Ruiz, from IRB Barcelona, and Dr. Georg E. Winter, from the CeMM Research Center for Molecular Medicine in Vienna (Austria) discussed the latest trends in proximity-inducing pharmacology, with special attention the role of computational biology in drug discovery. This innovative field, recognised with a Nobel Prize in 2004, opens new paths for treating previously incurable diseases by targeting protein degradation.
Focused on "CANCER IN CONTEXT," and hosted by Dr. Direna Alonso Curbelo, from IRB Barcelona, and Dr. Tuomas Tammela, from the Memorial Sloan Kettering Institute, the 40th conference featured advanced computational methods, innovative clinical studies, and novel technologies like artificial intelligence to study tumour evolution. This gathering highlighted emerging research paths and the potential for clinical translation, marking a significant stride in cancer research.
More information on the 39th conference: https://www.irbbarcelona.org/en/news/institutional/targeted-protein-degradation-therapeutic-strategy-focus-39th-barcelona-biomed
More information on the 40th conference: https://www.irbbarcelona.org/en/news/institutional/barcelona-biomed-conference-showcases-latest-insights-nature-and-evolutionary
